Treatment efficacy of pegintron alpha-2b and rivavirin for chronic hepatitis C patients with genotype 2 and high viral loads based on the dissapearance speed of serum HCV-RNA

Treatment efficacy of pegintron alpha-2b and rivavirin for chronic hepatitis C patients with genotype 2 and high viral loads based on the dissapearance speed of serum HCV-RNA - GLSG,2006,Pegintron

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000392

Enrollment

150

Registered

2012-12-31

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C with genotype 2 and high viral loads

Interventions

pegintron alpha-2b/rivavirin for 12 weeks for SRVR group pegintron alpha-2b/rivavirin for 24 weeks for RVR group pegintron alpha-2b/rivavirin for 48 weeks for LVR group pegintron alpha-2b/rivavirin fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C with genotype 2 positive test of HCV-RNA and pretreatment viral load is more than 100 KIU/mL negative test of HBsAg

Exclusion criteria

Exclusion criteria: chronic liver disease arising from other etiology allergy to interferon (IFN) during pregnancy severe complications-especially bone marrow, renal,cardiac, or respiratory dysfunction

Design outcomes

Primary

Measure	Time frame
virological responses and predictive factors associated each virological responses	—

Secondary

Measure	Time frame
safety, dose reduction and discontinuation	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@showa.gunma-u.ac.jp0272-20-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026